Da essentiel trombocytæmi er sjælden, blev Xagrid udpeget som "lægemiddel til sjældne sygdomme" den 29. december 2000.
Because the number of people with essential thrombocythaemia is low, the disease is rare, and Xagrid was designated as an ‘ orphan medicine’ (a medicine used in rare disease) on 29 December 2000.